Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Income from Continuing Operations (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Income from Continuing Operations for 3 consecutive years, with 25492000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Income from Continuing Operations fell 16.25% year-over-year to 25492000.0, compared with a TTM value of 123408000.0 through Dec 2021, down 88.32%, and an annual FY2024 reading of 76599000.0, up 9.39% over the prior year.
  • Income from Continuing Operations was 25492000.0 for Q4 2021 at Black Diamond Therapeutics, up from 34588000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 3830000.0 in Q1 2019 and bottomed at 34588000.0 in Q3 2021.
  • Average Income from Continuing Operations over 3 years is 18150750.0, with a median of 15733000.0 recorded in 2020.
  • The sharpest move saw Income from Continuing Operations plummeted 216.84% in 2020, then fell 16.25% in 2021.
  • Year by year, Income from Continuing Operations stood at 9904000.0 in 2019, then crashed by 121.42% to 21929000.0 in 2020, then decreased by 16.25% to 25492000.0 in 2021.
  • Business Quant data shows Income from Continuing Operations for BDTX at 25492000.0 in Q4 2021, 34588000.0 in Q3 2021, and 33767000.0 in Q2 2021.